SRSF protein kinase 1

Description:

Description
  • Accession: Q96SB4
  • Swissprot: SRPK1_HUMAN
  • Organism: Homo sapiens
  • Gene: SRPK1
  • Target class: Kinase

Drug Relations:

axitinib
oral Angiogenesis Inhibitor that inhibits the tyrosine kinase activities of both VEGFR and PDGFRbeta Bioactivity details MOA
crizotinib
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met. Bioactivity details MOA
midostaurin
Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFR-alfa/beta, VEGFR2, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors. Midostaurin also demonstrated the ability to inhibit KIT signaling, cell proliferation and histamine release and induce apoptosis in mast cells. Bioactivity details MOA
nintedanib
Boehringer Ingelheim's triple kinase inhibitor blocking VEGFR, PDGFR and FGFR Bioactivity details MOA
ruboxistaurin
inhibits protein kinase C beta Bioactivity details MOA
ruxolitinib
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function Bioactivity details MOA
sunitinib
inhibits VEGF-R2 and PDGF-Rbeta tyrosine kinase; has antineoplastic activity Bioactivity details MOA